Browse investing articles and stock analysis by Jake Lerch. Get expert financial insights and investment advice from The Motley Fool.

Full-year 2025 guidance: non-GAAP operating margin -- Expected between 23.5% and 24.5%, reflecting increases in sales and ...

BradyScan App Launch -- Announced as available on Android and Apple, supporting barcode generation, scanning, security ...

Acquisition Announcement -- VSE Corporation ( VSEC 0.75%) signed a definitive agreement to acquire Aero 3 for $350 million in ...

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive ...

gTLD process -- The ICANN 2026 round of new generic Top-Level Domains is intended to start in Q2 2026, with no future ...

Net Income -- $7.6 million, down from $9.3 million. Net income attributable to Karat ( KRT +1.51%) was $7.3 million, or $0.36 ...

Upcoming product launches -- AMP-007 inhalation on track for mid-2026 launch targeting a $1.5 billion market; generic ...

Total Revenue -- $21.2 million for the third quarter of 2025, up 16%, driven by MRI compatible IV infusion pump and ...

Q4 2025 guidance -- Projected total revenue of $371 million to $377 million; subscription revenue of $258 million to $261 ...

Relacorilant NDA updates -- FDA PDUFA date set for Dec. 30, 2025 (hypercortisolism); platinum-resistant ovarian cancer PDUFA ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.